Pictet & Cie (Europe) Sa Uni Qure N.V. Transaction History

Pictet & Cie (Europe) Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$4.82 - $6.93 $2,149 - $3,090	-446 Reduced 4.05%	10,577 $55,000
Q4 2023 Feb 09, 2024	SELL	$5.63 - $8.27 $2,387 - $3,506	-424 Reduced 3.7%	11,023 $74,000
Q3 2023 Nov 02, 2023	SELL	$6.71 - $11.83 $1,107 - $1,951	-165 Reduced 1.42%	11,447 $76,000
Q2 2023 Aug 08, 2023	SELL	$11.12 - $22.2 $7,661 - $15,295	-689 Reduced 5.6%	11,612 $133,000
Q1 2023 May 01, 2023	BUY	$18.7 - $23.07 $2,038 - $2,514	109 Added 0.89%	12,301 $247,000
Q4 2022 Feb 08, 2023	BUY	$18.12 - $27.32 $220,919 - $333,085	12,192 New	12,192 $0

156

40.5M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $757M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Pictet & Cie (Europe) Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet & Cie (Europe) Sa with notifications on news.